Critical Review Report: p-Methoxy-butyrylfentanyl by Brandt, SD
  
 
 
 
Critical Review Report: 
p-Methoxy-butyrylfentanyl 
 
 
Expert Committee on Drug Dependence 
Forty-first Meeting 
Geneva, 12-16 November 2018 
 
 
 
 
 
This report contains the views of an international group of experts, and does not necessarily represent the decisions 
or the stated policy of the World Health Organization 
 
 
 
 
 
41st ECDD (2018):  p-Methoxy-butyrylfentanyl     
 
 
 
Page 2 of 23 
© World Health Organization 2018 
All rights reserved. 
 
This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, 
before it has been formally published by the World Health Organization. The document may not be 
reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in 
whole, in any form or by any means without the permission of the World Health Organization.  
 
The designations employed and the presentation of the material in this publication do not imply the 
expression of any opinion whatsoever on the part of the World Health Organization concerning the legal 
status of any country, territory, city or area or of its authorities, or concerning the delimitation of its 
frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which 
there may not yet be full agreement.  
 
The mention of specific companies or of certain manufacturers’ products does not imply that they are 
endorsed or recommended by the World Health Organization in preference to others of a similar nature 
that are not mentioned. Errors and omissions excepted, the names of proprietary products are 
distinguished by initial capital letters.  
 
The World Health Organization does not warrant that the information contained in this publication is 
complete and correct and shall not be liable for any damages incurred as a result of its use. 
 
 
  
41st ECDD (2018):  p-Methoxy-butyrylfentanyl     
 
 
 
Page 3 of 23 
Contents 
Acknowledgements.................................................................................................................................. 5 
Executive Summary ....................................................................................................................................... 6 
1. Substance identification ................................................................................................................................... 9 
A. International Nonproprietary Name (INN) ................................................................................................................ 9 
B. Chemical Abstract Service (CAS) Registry Number ................................................................................................. 9 
C. Other Chemical Names ...................................................................................................................................................... 9 
D. Trade Names .......................................................................................................................................................................... 9 
E. Street Names.......................................................................................................................................................................... 9 
F. Physical Appearance ........................................................................................................................................................... 9 
G. WHO Review History .......................................................................................................................................................... 9 
2. Chemistry ......................................................................................................................................................... 10 
A. Chemical Name .................................................................................................................................................................. 10 
B. Chemical Structure ........................................................................................................................................................... 10 
C. Stereoisomers ..................................................................................................................................................................... 10 
D. Methods and Ease of Illicit Manufacturing ............................................................................................................ 10 
E. Chemical Properties ......................................................................................................................................................... 12 
F. Identification and Analysis ............................................................................................................................................. 12 
3. Ease of Convertibility Into Controlled Substances ........................................................................................ 12 
4. General Pharmacology ................................................................................................................................... 12 
A. Routes of administration and dosage ....................................................................................................................... 12 
B. Pharmacokinetics .............................................................................................................................................................. 13 
C. Pharmacodynamics .......................................................................................................................................................... 13 
5. Toxicology ........................................................................................................................................................ 15 
6. Adverse Reactions in Humans ........................................................................................................................ 15 
7. Dependence Potential .................................................................................................................................... 17 
A. Animal Studies .................................................................................................................................................................... 17 
B. Human Studies ................................................................................................................................................................... 17 
8. Abuse Potential ............................................................................................................................................... 18 
A. Animal Studies .................................................................................................................................................................... 18 
B. Human Studies ................................................................................................................................................................... 18 
9. Therapeutic Applications and Extent of Therapeutic Use and Epidemiology of Medical Use ................. 18 
10. Listing on the WHO Model List of Essential Medicines ............................................................................. 18 
11. Marketing Authorizations (as a Medicinal Product) ................................................................................. 18 
12. Industrial Use ................................................................................................................................................ 18 
13. Non-Medical Use, Abuse and Dependence ................................................................................................ 18 
41st ECDD (2018):  p-Methoxy-butyrylfentanyl     
 
 
 
Page 4 of 23 
14. Nature and Magnitude of Public Health Problems Related to Misuse, Abuse and Dependence .......... 18 
15. Licit Production, Consumption and International Trade ........................................................................... 19 
16. Illicit Manufacture and Traffic and Related Information .......................................................................... 19 
17. Current International Controls and Their Impact ...................................................................................... 19 
18. Current and Past National Controls ............................................................................................................ 20 
19. Other Medical and Scientific Matters Relevant for a Recommendation on the Scheduling of the 
Substance ................................................................................................................................................... 20 
References ................................................................................................................................................ 20 
 
  
41st ECDD (2018):  p-Methoxy-butyrylfentanyl     
 
 
 
Page 5 of 23 
 
Acknowledgements 
 
 
  
This report was prepared by the Secretariat of the Expert Committee on Drug Dependence (ECDD) 
within the Department of Essential Medicines and Health Products (EMP) of the World Health 
Organization (WHO), Geneva, Switzerland.  The WHO staff involved in the production of this 
document, developed under the overall guidance of Mariângela Simão (Assistant Director General, 
Access to Medicines, Vaccines, and Pharmaceuticals), Suzanne Hill (Director, Essential Medicines 
and Health Products), Gilles Forte, (Secretary of the Expert Committee on Drug Dependence) were 
Dilkushi Poovendran (Technical Officer, WHO Essential Medicines and Health Products) and Wil De 
Zwart (Technical Officer, WHO Essential Medicines and Health Products).   
 
This report was commissioned as a background document for a critical review for the 41st Expert 
Committee on Drug Dependence (ECDD). WHO would like to acknowledge Simon Brandt for 
drafting the report and Jurgen Rehm, Jakob Manthey, and Astrid Otto for the questionnaire 
analysis and writeup.  
 
The WHO Secretariat would also like to thank the European Monitoring Centre for Drugs and Drug 
Addiction (EMCCDA) for providing data on p-methoxy-butyrylfentanyl collected through the 
European Union Early Warning System, which includes data provided by Reitox National Focal 
Points in the EU Member States, Turkey and Norway, as well as the Europol National Units.     
41st ECDD (2018):  p-Methoxy-butyrylfentanyl     
 
 
 
Page 6 of 23 
Executive Summary 
 
 
Substance identification 
p-Methoxy-butyrylfentanyl (IUPAC name: N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-
yl]butanamide) is a synthetic analog of the opioid analgesic fentanyl. In Europe, it was first 
reported in 2015 followed by the Untied States of America later on. Samples obtained from 
seizures and collections suggest that p-methoxy-butyrylfentanyl occurs in powder, tablet, and 
nasal spray form.  
 
WHO Review History 
p-Methoxy-butyrylfentanyl has not been previously pre-reviewed or critically reviewed. 
 
Chemistry 
There is no specific information available about the routes of synthesis employed for the p-
methoxy-butyrylfentanyl products circulating on the drug market but straightforward methods for 
its preparation exist without requiring access to precursors that are controlled internationally. 
Routes of synthesis also exist that might require the use of a controlled precursor. 
 
Ease of convertibility into controlled substances 
p-Methoxy-butyrylfentanyl could be converted into various other fentanils but retaining the 4-
methoxyphenyl group would also render them uncontrolled at this time.  
 
Similarity to known substances / Effects on the central nervous system 
Data from human studies are not available but the information available so far suggests that the 
effects induced by p-methoxy-butyrylfentanyl are also shared by other synthetic opioids such as 
fentanyl and heroin.  
 
General pharmacology 
Pharmacological studies have shown that p-methoxy-butyrylfentanyl is qualitatively similar to 
fentanyl and heroin. p-Methoxy-butyrylfentanyl binds to μ-opioid receptors (MOR) with high 
selectivity over the κ- and δ-opioid receptors and has been shown to act as a partial agonist at 
MOR in a [35S]GTPγS binding assay. Similar to both fentanyl and morphine, p-methoxy-
butyrylfentanyl was also shown to induce locomotor activity and antinociceptive effects in mice. 
Antinociceptive effects were attenuated by pre-treatment with naltrexone.  
 
Toxicology 
Data on the toxicology of p-methoxy-butyrylfentanyl could not be identified.  
 
Adverse reactions in humans 
p-Methoxy-butyrylfentanyl has been detected in biological samples obtained from acute 
intoxication cases. Reported clinical features included reduced level of consciousness, respiratory 
depression, miosis, tachycardia, renal insufficiency, suspected aspiration, and apea. Naloxone 
treatments were required in some cases to reverse drug-induced respiratory depression. 
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Dependence potential 
No studies available. Experience with fentanyl and other synthetic opioids suggest that the 
dependence potential might extend to p-methoxy-butyrylfentanyl but further studies are 
warranted to explore this. 
 
Abuse potential 
Whilst no formal studies exist, the limited available information indicates that p-methoxy-
butyrylfentanyl is used by experimental users (psychonauts) including people who have a history 
of abusing other synthetic opioids and opiates. It seems likely that p-methoxy-butyrylfentanyl 
might be associated with abuse liability. 
 
Therapeutic applications / usefulness 
p-Methoxy-butyrylfentanyl is not known to have any therapeutic uses.  
 
Listing on WHO Model List of Essential Medicines 
p-Methoxy-butyrylfentanyl is not listed. 
 
Marketing authorizations 
p-Methoxy -butyrylfentanyl is not known to have any marketing authorizations. 
 
Industrial use 
p-Methoxy-butyrylfentanyl is not known to have any agricultural, industrial or cosmetic uses even 
though it is available for purchase as a ‘research chemical’. 
 
Non-medical use 
The mode of use may involve the combinational use (intentionally or unintentionally) of other 
drugs and users may be unaware of the exact dose or compound being ingested (by whatever 
route). Similar to other fentanils, p-methoxy-butyrylfentanyl may be administered as a solution 
(e.g. using nasal sprays), orally as a powder (including in capsules or tablets), or by insufflation of a 
powder; it can also be administered sublingually or intranasally via a spray; administered by 
injection (intramuscular or intravenous) or inhaled by vaporizing.  
 
Nature and magnitude of public health problems 
Use of p-methoxy-butyrylfentanyl appears to be limited to recreational substance users rather 
than the general population. Marginalized and vulnerable opioid users including those who inject 
such substances also use fentanyl analogs. However, users may not be aware of using them and 
the high potency associated with fentanyl analogs might result in increased risks of life-
threatening overdoses. At the same time, fentanyl and its analogs pose a serious risk of accidental 
exposure to products with the potential for subsequent poisoning of the public, law enforcement 
and emergency personnel, as well as medical/laboratory personnel. 
 
Licit production, consumption, and international trade 
p-Methoxy-butyrylfentanyl is not known to have any agricultural, industrial or cosmetic uses even 
though it is available for purchase as a ‘research chemical’. 
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Illicit manufacture and traffic 
So far the total number of reports describing the identification of p-methoxy-butyrylfentanyl is 
very limited. p-Methoxy-butyrylfentanyl can be purchased from Internet retailers. 
 
Current international controls and their impact 
p-Methoxy-butyrylfentanyl is not controlled under the 1961, 1971 or 1988 United Nations 
Conventions. 
 
Current and past national controls 
See Annex A 
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1.  Substance identification  
A. International Nonproprietary Name (INN) 
Not applicable. 
B. Chemical Abstract Service (CAS) Registry Number 
2088842-68-4 (free base) 
C. Other Chemical Names 
N-(4-Methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide 
N-(4-Methoxyphenyl)-N-(1-phenethyl-4-piperidinyl)butanamide 
 p-Methoxy-butyrylfentanyl 
para-Methoxy-butyrylfentanyl 
4-Methoxy-butyrylfentanyl 
4′-Methoxy-butyryfentanyl 
p-Methoxy-butanoylfentanyl 
para-Methoxy-butanoylfentanyl 
4-Methoxy-butanoylfentanyl 
4′-Methoxy-butanoylfentanyl 
p-Methoxy-butyrfentanyl 
para-Methoxy-butyrfentanyl 
4-Methoxy-butyrfentanyl 
4′-Methoxy-butyrfentanyl 
D. Trade Names 
Not applicable. 
E. Street Names 
p-MeO-BF; 4-MeO-BF; street names also include chemical names. 
F. Physical Appearance 
The hydrochloride salt of p-methoxy-butyrylfentanyl has been described as a white 
powder1 and a neat solid.2 In its pure form, p-methoxy-butyrylfentanyl 
hydrochloride is expected to be odorless. 
G. WHO Review History 
p-Methoxy-butyrylfentanyl has not been previously pre-reviewed or critically 
reviewed. A direct critical review is proposed based on information brought to 
WHO’s attention that p-methoxy-butyrylfentanyl is clandestinely manufactured, of 
especially serious risk to public health and society, and of no recognized therapeutic 
use by any party. Preliminary data collected from literature and different countries 
indicated that this substance may cause substantial harm and that it has no medical 
use. 
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2. Chemistry 
A. Chemical Name 
IUPAC Name:  
   N-(4-Methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide 
CA Index Name:  
N-(4-Methoxyphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]butanamide 
B. Chemical Structure 
Free base: 
 
 
Molecular Formula: C24H32N2O2 
Molecular Weight: 380.53 g/mol 
  
C. Stereoisomers 
Not applicable. 
D. Methods and Ease of Illicit Manufacturing 
Information on the synthesis of p-methoxy-butyrylfentanyl products encountered 
on the market could not be identified. It is expected that the methods used for the 
synthesis of fentanyle.g.3-7 are equally applicable to p-methoxy-butyrylfentanyl by 
changing the widely available reagents accordingly. One common procedure is 
shown in Figure 1A and is based on the published synthesis of p-methoxy-
fentanyl,e.g.8 which is comparable to one process describing the preparation of 
fentanyl available on the Internet.9 1-(2-Phenylethyl)piperidin-4-one (a) (also known 
as N-phenethyl-4-piperidone, NPP) is condensed with p-methoxyaniline (p-
anisidine) followed by reduction of the imine (b) to afford N-(4-methoxyphenyl)-1-
(2-phenylethyl)piperidin-4-amine as intermediate (c). Acylation with butanoic 
anhydride (or butanoyl chloride) yields the product p-methoxy-butyrylfentanyl (d). 
However, NPP is listed in Table 1 of the United Nations Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic Substances of 1988.10 Intermediate (c) 
represents the methoxylated analog of N-phenyl-1-(2-phenylethyl)piperidin-4-
amine (4-ANPP), which is a controlled precursor10 used for the preparation of 
fentanyl and other analogs. 4-MeO-ANPP is however currently not controlled. 
 
O
NN
O
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Figure 1. Examples of potential procedures used for the preparation of p-methoxy-butyrylfentanyl. A. Adapting the 
procedure described for the preparation of p-methoxy-fentanyl.
e.g.8
 i) 4-MeO(C6H4)NH2; ii) NaBH4; iii) 
(CH3CH2CH2CO)2O. B. Potential synthesis of p-methoxy-butyrylfentanyl (f) following one of the earliest procedures 
employed by Janssen.
3
 i) 4-MeO(C6H4)NH2; ii) acid catalyst (e.g. pTsOH); ii: LiAlH4; iii) (CH3CH2CH2CO)2O; iv) H2, Pd-C; v) 
PhCH2CH2Cl, KI, Na2CO3. 
 
Figure 1B outlines another potential approach based on one of the earliest 
procedures used for the preparation of fentanyl.3 p-Methoxy-butyrylfentanyl was 
captured by the Janssen patent but not explicitly described. The starting material 1-
benzylpiperidin-4-one (a) undergoes reductive amination with 4-methoxyaniline 
(via (b)) to form 1-benzyl-N-(4-methoxyphenyl)piperidin-4-amine (c), which 
undergoes acylation with either butanoic anhydride or butanoyl chloride to afford 
N-(1-benzylpiperidin-4-yl)-N-(4-methoxyphenyl)butanamide (d). Debenzylation by 
hydrogenation provides access to N-(4-methoxyphenyl)-N-(piperidin-4-
yl)butanamide (e). Alkylation of the piperidine nitrogen with either (2-
chloroethyl)benzene or (2-bromoethyl)benzene yields p-methoxy-butyrylfentanyl 
(f). 
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E. Chemical Properties 
Melting point 
Information could not be identified. 
Boiling point 
Information could not be identified. 
Solubility 
The free base is expected to be only sparingly soluble in water. A collected 
hydrochloride salt sample identified as p-methoxy-butyrylfentanyl was noted as 
being soluble in methanol and water and partially soluble in dichloromethane.11  
F. Identification and Analysis  
 
Identification, especially when available in larger quantities than normally 
encountered in forensic toxicological work, is straightforward. Results from 
analytical studies have been published and include data on gas chromatography 
electron ionization mass spectrometry (MS),1, 11, 12 electrospray ionization MS,13, 14 
nuclear magnetic resonance spectroscopy,1, 11  immunoassays,15 and Fourier 
transform infrared spectroscopy.1, 11  
 
Analytical challenges may arise, for example when dealing with closely related 
isomers such as N-(4-methoxyphenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-
yl]propanamide (p-methoxy-isobutyrylfentanyl). In addition, both of these fentanils 
can also exist in the ortho- (2-methoxyphenyl) or meta-methoxy (3-methoxyphenyl) 
forms, which adds to the complexity. The implementation of adequate separation 
techniques might be needed to reduce the potential for misidentification, especially 
when dealing with samples (e.g. biological) that may only contain trace quantities. 
3. Ease of Convertibility Into Controlled Substances 
No information available. A conversion of p-methoxy-butyrylfentanyl to a range of 
other fentanyl analogs is feasible but the retention of the 4-methoxyphenyl group 
would lead to substances that are also currently not controlled under the UN 
system.  
 
4. General Pharmacology 
A. Routes of administration and dosage 
Similar to other fentanils,16, 17 p-methoxy-butyrylfentanyl may be administered as a 
solution (e.g. using nasal sprays), orally as a powder (including in capsules or 
tablets), or by insufflation of a powder; it can also be administered sublingually or 
intranasally via a spray; administered by injection (intramuscular or intravenous) or 
inhaled by vaporizing. Information received by the EMCDDA based on analyses of 
seized and collected material and published literature involving adverse suggests 
the existence of p-methoxy-butyrylfentanyl-containing powders, tablets and nasal 
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spray formulations.13, 18 Information on p-methoxy-butyrylfentanyl shared in the 
form of user reports is limited, which means that relievable information on doses 
could not be identified. In addition, estimating the doses administered by users may 
not be possible as this appears to depend on factors such as the tolerance of the 
users, the use of other drugs, desired effects, and the route of administration. Case 
report literature suggests that p-methoxy-butyrylfentanyl-containing pills and nasal 
sprays were ingested.13 
B. Pharmacokinetics 
Detailed information specifically on p-methoxy-butyrylfentanyl could not be 
identified but it appears likely that at least some of the metabolic transformation 
products follows similar mechanisms of formation that were seen with other 
fentanils.e.g.13, 16, 19 Regarding the duration of effects, some estimations exist online. 
“Insufflated” routes of administration: onset 1–2 min; duration 30–75 min; after 
effects 1–2 h. Oral administration: onset 5–15 min; duration 45–120 min; after 
effects 1–2 h.20 For the reasons mentioned above however, such estimations 
should be viewed with caution. 
C. Pharmacodynamics 
In vitro data: 
 
Current available data suggest that p-methoxy-butyrylfentanyl, similar to morphine 
and fentanyl, binds to μ-opioid receptors (MOR) with high selectivity over the κ- 
and δ-opioid receptors (KOR and DOR) (Table 1).21 Functional studies using the 
[35S]GTPγS binding assay also demonstrated that p-methoxy-butyrylfentanyl acted 
as a partial agonist at MOR with a far reduced efficacy at DOR and agonist 
properties at KOR. Its potency for binding and MOR activation was significantly 
lower compared to morphine and fentanyl (Table 1).  
 
Table 1. Receptor binding and functional activity data for p-methoxy-butyrylfentanyl (modified from
21
).
a
 
MOR pMBF b Morphine Fentanyl DAMGO Naltrexone 
[3H]DAMGO binding Ki (nM) 
IC50 (nM) 
Hill coefficient 
1.485 ± 0.097 
9.91 ± 0.40 
-0.87 ± 0.03 
0.213 ± 0.019 
1.432 
-0.95 ± 0.02 
0.150 ± 0.030 
1.00 
-0.72 ± 0.07 
0.1313 ± 0.0050 
0.883 
-0.89 ± 0.06 
0.0793 ± 0.0042 
0.532 
-0.81 ± 0.36 
[35S]GTPγS binding 
Stimulation EC50 (nM) 
Maximal stimulation (%) c 
pMBF b 
72 ± 11 
55.2 ± 3.7 
Morphine 
31.0 ± 8.2 
83.3 ± 5.5 
Fentanyl 
17.9 ± 4.3 
81.2 ± 7.4 
DAMGO 
21.4 ± 4.2 
96.8 ± 1.9 
– 
– 
– 
DOR pMBF b Morphine Fentanyl DPDPE-OH Naltrexone 
[3H]DPDPE binding Ki (nM) 
IC50 (nM) 
593 ± 51 
988 ± 96 
111 ± 14 
182 
242 ± 20 
391 
2.96 ± 0.57 
5.0 
14.2 ± 3.1 
23.8 
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In vivo data: 
 
Locomotor activity studies (adult male CFW mice; subcutaneous administration; 
distances traveled during 120 min test sessions recorded in 10 min intervals) have 
been carried out comparing p-methoxy-butyrylfentanyl (tested 0.1, 1, and 10 
mg/kg) with fentanyl (0.1, 1 and 10 mg/kg) and morphine (1, 10, 100 and 180 
mg/kg).22  
 
p-Methoxy-butyrylfentanyl significantly increased distance traveled during all time 
intervals at 10 mg/kg (10–120 min). Fentanyl increased locomotion at 1 mg/kg (10–
120 min), and 10 mg/kg (30–120 min), and morphine increased distances traveled 
at 10 mg/kg (40–90 min), 100 mg/kg (20–120 min), and 180 mg/kg (20–120 min). 
Hill coefficient -0.98 ± 0.07 -0.96 ± 0.02 -0.93 ± 0.09 -0.94 ± 0.10 -1.03 ± 0.12 
[35S]GTPγS binding 
Stimulation EC50 (nM) 
Maximal stimulation (%) c 
pMBF b 
2,850 ± 920 
13.07 ± 0.58 
Morphine 
870 ± 140 
77.3 ± 2.3 
Fentanyl 
1,190 ± 140 
58.0 ± 4.2 
DPDPE-OH 
7.22 ± 0.38 
100.97 ± 0.97 
– 
– 
– 
KOR pMBF b Morphine Fentanyl U-50,488H Nor-BNI 
[3H]U-69,593 binding Ki (nM) 
IC50 (nM) 
Hill coefficient 
136 ± 27 
308 ± 63 
-0.97 ± 0.09 
27.9 ± 2.7  
63.4 
-0.98 ± 0.06 
194 ± 20  
436 
-1.19 ± 0.17 
0.155 ± 0.048  
0.35 
-0.70 ± 0.03 
0.42 ± 0.16  
0.86 
-1.11 ± 0.23 
[35S]GTPγS binding 
Stimulation EC50 (nM) 
Maximal stimulation (%) c 
pMBF b 
193 ± 31 
80.5 ± 3.3 
Morphine 
83 ± 23 
86.8 ± 6.0 
Fentanyl 
362 ± 47 
72.9 ± 3.2 
U-50,488H 
1.15 ± 0.22 
93.6 ± 2.2 
– 
– 
– 
a
 In receptor binding experiments, transfected Chinese hamster ovary (CHO) cells expressing human δ- and κ-opioid receptors and rat μ-opioid 
receptors were used. DOR: delta opioid receptor; KOR: kappa opioid receptor; MOR: mu opioid receptor; DAMGO: Tyr-Ala-Gly-N-Me-Phe-Gly-
ol, DPDPE-OH: Tyr-Pen-Gly-Phe-Pen-OH [disulfide bridge: 2-5]; U-69,593: (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-
yl]-benzeneacetamide; 
 
U-50,488H: trans-(±)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide methanesulfonate salt; 
Nor-BNI: norbinaltorphimine; U-69,593: (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide. SEM: 
standard error of the mean.  
Numbers represent the means ± SEM from at least three independent experiments, each conducted with duplicate determinations. Standard 
compounds were the agonists DPDPE (delta), U50,488H (kappa) and DAMGO (mu) and the antagonists naltrexone (delta and mu) and nor-BNI 
(kappa). 
c
 Maximal stimulation by test compound is normalized to the maximal stimulation by DPDPE (delta), U50,488H (kappa) or DAMGO (mu) above 
basal. Negative values indicate inhibition of basal [
35
S]GTPγS binding. 
b
 pMBF:  p-methoxy-butyrylfentanyl. 
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The dose-dependent activation of locomotor activity was confirmed to be 
qualitatively similar to fentanyl and morphine. As far as the total distances traveled 
were concerned, fentanyl induced the largest increase at 1 mg/kg. The total 
distances traveled following administration of p-methoxy-butyrylfentanyl (10 
mg/kg) and morphine (100 and 180 mg/kg) were comparable.22 
 
Antinociceptive effects (warm water tail-withdrawal test, 50°C, adult male CFW 
mice; subcutaneous administration) have been investigated and it was confirmed 
that p-methoxy-butyrylfentanyl increased the withdrawal latency consistent with 
delayed withdrawal times also observed with fentanyl and morphine used for 
comparison. Significant dose-dependent increases in tail withdrawal latencies were 
observed for all test drugs, which were attenuated by pre-treatment with 
naltrexone (Table 2).23 In this assay, p-methoxy-butyrylfentanyl was almost 
equipotent to fentanyl and 74-times more potent than morphine (Table 2). p-
Methoxy-butyrylfentanyl showed a higher potency in eliciting antinociception 
compared to locomotor stimulation. Straub tail was observed after administering all 
three drugs during tail-withdrawal tests and it was stated that other obvious and 
unusual signs were not observed.23  
 
Table 2. Antinociceptive effects using the warm-water tail-withdrawal procedure.
23
  
Test drug ED50 (mg/kg) 
p-Methoxy-butyrylfentanyl 0.1057 
p-Methoxy-butyrylfentanyl + naltrexone (1 mg/kg) 3.9860 
Fentanyl  0.0801 
Fentanyl + naltrexone (1 mg/kg) 0.3162 
Morphine 7.8210 
Morphine + naltrexone (1 mg/kg) 11.5900 
 
5. Toxicology 
No information could be identified.  
6. Adverse Reactions in Humans 
The US Centers for Disease Control and Prevention estimated that drug overdose 
deaths involving synthetic opioids (excluding methadone) for the 12-month period 
ending in January of 2017 (20,145 deaths) increased significantly compared to the 
cases counted for the period ending in January of 2016 (9,945 deaths).24 However, 
specific information related to a causal relationship of p-methoxy-butyrylfentanyl 
with adverse reactions is currently very limited.  
 
Three cases of acute intoxications associated with p-methoxy-butyrylfentanyl and 
one case involving p-methoxy-butyrylfentanyl and furanylfentanyl (N-phenyl-N-[1-
(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide)25, 26 occurring between April 
and November 2015 in Sweden have been published (Table 3). Clinical features 
included reduced level of consciousness, respiratory depression, miosis, 
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tachycardia, renal insufficiency, suspected aspiration, and apea.13 In three of the 
four cases, naloxone treatment was needed to reverse respiratory depression.  
 
Table 3. Acute intoxication cases involving the detection of p-methoxy-butyrylfentanyl in Sweden 
Year a Patent, 
age 
Comments b Ref 
2016 F, 29 Patient reported intake of unknown new psychoactive 
substance and tramadol. Detection of p-methoxy-
butyrylfentanyl (1 h after admission): 1.3 ng/mL (serum), 
5.1 ng/mmol creatinine (urine).  
 
GCS 15, miotic pupils, HR 134/min, BP 143/93 mmHg on 
ambulance arrival. Two days of hospital care.  
 
Naloxone treatment: no 
 
Other substances detected (including some that may 
have been treatment-related): butyrylfentanyl, 4F-
butyrylfentanyl, phytocannabinoids, tramadol, O-des- 
methyltramadol, and desmethyldiazepam. 
 
13 
2016 M, 28 Patient reported intake of unknown opioids and 
benzodiazepines. Detection of p-methoxy-butyrylfentanyl 
(promptly after admission): 3.1 ng/mL (serum).  
 
RLS 8, RR 7/min, SpO2 83%, miotic pupils, pH 7.24, pCO2 
6.4 kPa, pO2 10.3 kPa, lactate 4.7 mmol/L, standard-
bicarbonate 19.0 mmol/L, base excess -6 mmol/L, S-
creatinine 163 mg/L, HR 117/min on ambulance arrival. P-
troponin I 1.2 μg/L, S-ALT 10.4 μkat/L, S-AST 9.0 μkat/L. 
Two days of hospital care. 
 
Naloxone treatment: 0.4 mg iv and 0.2 mg iv. 
 
Other substances detected (including some that may 
have been treatment-related): 4F-butyrylfentanyl, 
alprazolam, OH-alprazolam, 7-amino-clonazepam, 
benzoylecgonine, clonazepam, cocaine, O- 
desmethyltramadol, diazepam, and oxazepam.  
13 
2016 M, 34 Patient reported intake of unknown drug tablet and 
fentanyl. Detection of p-methoxy-butyrylfentanyl (1 h 
after admission): 11.9 ng/mmol creatinine (urine).  
 
RLS 8, temporary apnoea, miotic pupils, HR 100/min. Two 
days of hospital care. 
13 
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Naloxone treatment: 0.4 mg iv 
 
Other substances detected (including some that may 
have been treatment-related): 4F-butyrylfentanyl, 
clonazolam, GHB, fentanyl. 
2016 M, 22 Patient reported intake of unknown new psychoactive 
substance (nasal spray; nasal insufflation and 
intramuscular administration) and clonazepam. Detection 
of p-methoxy-butyrylfentanyl and furanylfentanyl 
(promptly after admission): 11.0/4.4 ng/mL (serum); 
51.3/9.2 ng/mmol creatinine (urine). Two days of hospital 
care. 
 
Naloxone treatment: 0.4 mg iv 
 
RLS 8, apnea and cyanosis on ambulance arrival. Initial 
VBG: pH 7.27, pCO2 8.0 kPa, pO2 4.8 kPa, SpO2 58%. BT 36 
°C, P-creatinine 113 μg/ L, P-ALT 1.2 μkat/L, P-AST 0.8 
μkat/ L. HR 120/min. 
 
Other substances detected (including some that may 
have been treatment-related): EtG/EtS, MDPHP, 
pregabalin, and clonazepam. 
13 
a
 Year of publication. Cases occurred in 2015. 
 
b 
RLS: Reaction Level Scale; GCS: Glasgow Coma Scale; BT: body temperature; HR: heart rate; BP: blood 
pressure; RR: respiratory rate; SaO2/SpO2: oxygen saturation; S: serum; P: plasma; ALT: alanine 
aminotransferase; AST: aspartate aminotransferase; VBG: venous blood gas; EtG/EtS: ethanol metabolites 
ethyl glucuronide and ethyl sulfate;; MDPHP: α-pyrrolidinoheptanophenone. 
 
7. Dependence Potential 
A. Animal Studies 
Studies that have investigated the dependence potential of p-methoxy-
butyrylfentanyl in animals could not be identified. 
B. Human Studies 
Studies that have investigated the dependence potential of p-methoxy-
butyrylfentanyl in humans could not be identified. However, it is well established 
that opioid analgesics such as fentanyl can induce tolerance and dependence. 
Further research might be required in order to investigate these effects with p-
methoxy-butyrylfentanyl. 
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8. Abuse Potential 
A. Animal Studies 
Studies that have investigated the abuse potential of p-methoxy-butyrylfentanyl in 
animals could not be identified.  
B. Human Studies 
Studies that have investigated the abuse potential of p-methoxy-butyrylfentanyl in 
humans could not be identified although cases of analytically confirmed 
recreational use have been reported (Section 6). 
9. Therapeutic Applications and Extent of Therapeutic Use and Epidemiology of 
Medical Use 
Information about therapeutic use could not be identified. 
10. Listing on the WHO Model List of Essential Medicines 
p-Methoxy-butyrylfentanyl is not listed. 
11. Marketing Authorizations (as a Medicinal Product) 
p-Methoxy-butyrylfentanyl was never marketed as a medicinal product.   
12. Industrial Use 
Information about recorded industrial use could not be identified. 
13. Non-Medical Use, Abuse and Dependence 
Surveys that systematically assess the prevalence of p-methoxy-butyrylfentanyl use within 
the general population are not available. The detection of p-methoxy-butyrylfentanyl in 
biological fluids confirms that this substance is used recreationally (Section 6). Experience 
with fentanyl and other analogs has shown that the use of such substances is often 
associated with individuals who might be abusing/misusing heroin and prescription opioid 
analgesics and heroin. 
14. Nature and Magnitude of Public Health Problems Related to Misuse, Abuse and 
Dependence 
Data on the effects of p-methoxy-butyrylfentanyl on the ability to drive and operate 
machines could not be identified. Since it is well established that opioid analgesics, such as 
fentanyl, impact on the mental and physical ability required for driving and operating 
machinery, it is likely that this might also extend to p-methoxy-butyrylfentanyl. Some of 
these substances may be sold as another substance and/or are not always labeled, a 
phenomenon that has been observed with the use of other fentanyl analogs. Examples 
exist where fentanyl analogs were detected as an adulterant in samples of heroin obtained 
from the cryptomarket.27 The US Drug Enforcement Administration reported the detection 
of cocaine samples adulterated with fentanyl and fentanyl analogs, which occurred in 
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seized samples obtained in the period from 2016–2017 in Florida (USA).28 Marginalized and 
vulnerable opioid users including those who inject such substances also use fentanyl 
analogs. However, users may not be aware of using them and the high potency associated 
with fentanyl analogs might result in increased risks of life-threatening overdoses. 
 
The observation that p-methoxy-butyrylfentanyl and other analogs are also available in the 
form of nasal sprays raises questions as to whether these dosage forms might render the 
use of fentanils more attractive and/or socially acceptable.17 Further studies are warranted 
to assess whether this might be associated with the attraction of new user groups.  
 
The high potency of fentanyl and its analogs pose a serious risk of accidental exposure to 
products with the potential for subsequent poisoning of the public, law enforcement and 
emergency personnel, as well as medical/laboratory personnel.16, 17 
15. Licit Production, Consumption and International Trade 
It is used as a reference material for scientific research. It is not known to have any 
agricultural, industrial or cosmetic uses even though it is available for purchase as a 
‘research chemical’.  
 
Please refer to Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
16. Illicit Manufacture and Traffic and Related Information 
Reports have been received from the European Early-Warning System on new 
psychoactive substances that p-methoxy-butyrylfentanyl (first notified to EMCDDA in 
August 201529) was encountered in seizures and collected specimen (powder and tablets) 
in Slovenia and Sweden.18 
 
The background information and evaluation of ‘Three Factor Analysis’ (Factors 4, 5 and 6) 
for temporary scheduling document30 states that the identification of p-methoxy-
butyrylfentanyl was featured once based on queries (November 3, 2017) of the National 
Forensic Laboratory Information System (NFLIS), which is dedicated to the collection of 
drug cases submitted by State and local laboratories in the USA.  
 
Detections of p-methoxy-butyrylfentanyl have also been reported to the United Nations 
Office on Drugs and Crime’s (UNODC) Early Warning Advisory on New Psychoactive 
Substances by Slovenia and Sweden in 2015 (as of 25 August 2018).31 
 
Please also refer to Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
17. Current International Controls and Their Impact 
p-Methoxy-butyrylfentanyl is not controlled under the 1961, 1971 or 1988 United Nations 
Conventions. 
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18. Current and Past National Controls 
Refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
 
19. Other Medical and Scientific Matters Relevant for a Recommendation on the 
Scheduling of the Substance 
Detections of p-methoxy-butyrylfentanyl may be under-reported given that the substance 
might not be routinely screened for in all laboratories receiving samples for analysis.  
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